Advertisement

Chinese Journal of Cancer Research

, Volume 22, Issue 1, pp 68–72 | Cite as

Effect of survivin-siRNA on drug sensitivity of osteosarcoma cell line MG-63

  • Jing-Wei Wang
  • Yi Liu
  • Hai-mei Tian
  • Wei ZhangEmail author
Original Article

Abstract

Objective

Survivin is one of the apoptosis inhibitor genes and is rarely expressed in adulttissues. However, survivin expression has been detected in various human cancers and correlations have been recognized between the level of expression of this gene in tumors and prognosis. In this study, we investigated the effect of Survivin-siRNA on the drug sensitivity of osteosarcoma cell line MG-63.

Methods

Two siRNAs (Survivin-siRNA1, Survivin-siRNA2) specifically targeting Survivin gene were chemically synthesized and transfected into MG-63 cells. The Survivin mRNA level was detected by reverse transcription-polymerase chain reaction (RT-PCR). The survivin protein expression and cell apoptosis rate were analyzed by flow cytometry (FCM). The 50% inhibition concentration (IC50) of cisplatin (DDP) and adriamycin (ADM) on MG-63 cells was determined by MTT method.

Results

Two short siRNA targeting survivin down-regulated the transcription of survivin gene dramatically and elevated apoptosis rate. They increased the drug sensitivity of MG-63 cells to ADM by five-fold and to DDP by nine-fold.

Conclusion

Validated Survivin specific siRNA can effectively inhibit Survivin expression in survivin-overexpressing osteosarcoma MG-63 cell line and enhance the drug sensitivity of MG-63 cell line to ADM and DDP. Short survivin-siRNA mediated gene silencing may be a useful therapeutic strategy for osteosarcoma. These results suggest that survivin might be helpful for diagnosis of osteosarcoma and survivin siRNA combined with adriamycin or cisplatin may be a feasible strategy to enhance the effects of chemotherapy in patients with osteosarcoma.

Key words

Survivin siRNA RNAi Osteosarcoma Drug sensitivity 

CLC number

R73-36 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Picci P, Ferrari S, Bacci G, et al. Treatment recommendations for osteosarcoma and adult soft-tissue sarcomas [J]. Drugs 1994; 47:82–92.CrossRefPubMedGoogle Scholar
  2. [2]
    Ikeguchi M, Kaibara N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma [J]. Br J Cancer 2002; 87:883–887.CrossRefPubMedGoogle Scholar
  3. [3]
    Wall NR, O’Connor DS, Plescia J, et al. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis [J]. Cancer Res 2003; 63:230–235.PubMedGoogle Scholar
  4. [4]
    Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J]. Nat Med 1997; 3:917–921.CrossRefPubMedGoogle Scholar
  5. [5]
    R-del C, Haas J, Groth A, et al. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor [J]. Int J Radiat Oncol Biol Phys 2003; 55:1341–1347.Google Scholar
  6. [6]
    Olie RA, Sim-es-Wüst AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy [J]. Cancer Res 2000; 60:2805–2809.PubMedGoogle Scholar
  7. [7]
    Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions [J]. Drug Resist Updat 2002; 5:65–72.CrossRefPubMedGoogle Scholar
  8. [8]
    Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J]. Nat Med 1997; 3:917–921.CrossRefPubMedGoogle Scholar
  9. [9]
    Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin [J]. Nature 1998; 396:580–584.CrossRefPubMedGoogle Scholar
  10. [10]
    Asanuma K, Moriai R, Yajima T, et al. Survivin as a radioresistance factor in pancreatic cancer [J]. Jpn J Cancer Res 2000; 91:1204–1209.PubMedGoogle Scholar
  11. [11]
    Ikeguchi M, Liu J, Kaibara N. Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment [J]. Apoptosis 2002; 7:23–29.CrossRefPubMedGoogle Scholar
  12. [12]
    Bernstein E, Denli AM, Hannon GJ. The rest is silence [J]. RNA 2001; 7:1509–1521.PubMedGoogle Scholar
  13. [13]
    Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells [J]. Nature 2001; 411:494–498.CrossRefPubMedGoogle Scholar
  14. [14]
    Williams NS, Gaynor RB, Scoggin S, et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference [J]. Clin Cancer Res 2003; 9:931–946.PubMedGoogle Scholar

Copyright information

© Chinese Anti-Cancer Association and Springer Berlin Heidelberg 2010

Authors and Affiliations

  • Jing-Wei Wang
    • 1
  • Yi Liu
    • 2
  • Hai-mei Tian
    • 2
  • Wei Zhang
    • 2
    Email author
  1. 1.Department of Orthopaedic SurgeryTangshan Worker HospitalTangshanChina
  2. 2.Tumor Marker Research Center, Cancer Institute & HospitalChinese Academy of Medical Sciences, Peking Union Medical CollegeBeijingChina

Personalised recommendations